Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: how big is the problem? which patients are at risk?

Schloot, Nanette C; Haupt, Axel; Schütt, Morten; Badenhoop, Klaus; Laimer, Markus; Nicolay, Claudia; Reaney, Matthew; Fink, Katharina; Holl, Reinhard W (2016). Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: how big is the problem? which patients are at risk? Diabetes/metabolism research and reviews, 32(3), pp. 316-324. Wiley 10.1002/dmrr.2722

[img] Text
dmrr2722.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (434kB)

BACKGROUND

We investigated the rate of severe hypoglycemic events and confounding factors in patients with type-2-diabetes treated with sulfonylurea (SU) at specialized diabetes centers, documented in the German/Austrian DPV-Wiss-database.

METHODS

Data from 29,485 SU-treated patients were analyzed (median[IQR] age 70.8[62.2-77.8]yrs, diabetes-duration 8.2[4.3-12.8]yrs). The primary objective was to estimate the event-rate of severe hypoglycemia (requiring external help, causing unconsciousness/coma/convulsion and/or emergency.hospitalization). Secondary objectives included exploration of confounding risk-factors through group-comparison and Poisson-regression.

RESULTS

Severe hypoglycemic events were reported in 826(2.8%) of all patients during their most recent year of SU-treatment. Of these, n = 531(1.8%) had coma, n = 501(1.7%) were hospitalized at least once. The adjusted event-rate of severe hypoglycemia [95%CI] was 3.9[3.7-4.2] events/100 patient-years (coma: 1.9[1.8-2.1]; hospitalization: 1.6[1.5-1.8]). Adjusted event-rates by diabetes-treatment were 6.7 (SU + insulin), 4.9 (SU + insulin + other OAD), 3.1 (SU + other OAD), and 3.8 (SU only). Patients with ≥1 severe event were older (p < 0.001) and had longer diabetes-duration (p = 0.020) than patients without severe events. Participation in educational diabetes-programs and indirect measures of insulin-resistance (increased BMI, plasma-triglycerides) were associated with fewer events (all p < 0.001). Impaired renal function was common (N = 3,113 eGFR ≤30 mL/min) and associated with an increased rate of severe events (≤30 mL/min: 7.7; 30-60 mL/min: 4.8; >60 mL/min: 3.9).

CONCLUSIONS

These real-life data showed a rate of severe hypoglycemia of 3.9/100 patient-years in SU-treated patients from specialized diabetes centers. Higher risk was associated with known risk-factors including lack of diabetes-education, older age, and decreased eGFR, but also with lower BMI and lower triglyceride-levels, suggesting that SU-treatment in those patients should be considered with caution. This article is protected by copyright. All rights reserved.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Laimer, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1520-7560

Publisher:

Wiley

Language:

English

Submitter:

Markus Laimer

Date Deposited:

30 Mar 2016 11:18

Last Modified:

05 Dec 2022 14:52

Publisher DOI:

10.1002/dmrr.2722

PubMed ID:

26409039

Uncontrolled Keywords:

type 2 diabetes; sulfonylurea; hypoglycemia; DPV-Wiss; real-life data

BORIS DOI:

10.7892/boris.77608

URI:

https://boris.unibe.ch/id/eprint/77608

Actions (login required)

Edit item Edit item
Provide Feedback